此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Serplulimab Plus Bevacizumab and Chemotherapy for Left-Sided, KRAS/NRAS/BRAF Wild-Type Colorectal Cancer After First-Line Anti-EGFR Therapy (SALVAGE)

2026年11月16日 更新者:Jingdong Zhang、China Medical University, China

A Randomized, Controlled, Multicenter, Phase 2 Clinical Study of Serplulimab Combined With Bevacizumab and Chemotherapy in Patients With Left-Sided, KRAS/NRAS/BRAF Wild-Type Colorectal Cancer Who Failed First-Line Anti-EGFR Monoclonal Antibody Therapy

This is a prospective, multicenter, randomized, controlled Phase 2 clinical study to evaluate the effectiveness and safety of adding serplulimab (an immunotherapy drug that targets PD-1) to standard second-line treatment with bevacizumab and chemotherapy. The study enrolls adult patients with advanced or metastatic, left-sided colorectal cancer whose tumors are microsatellite stable (MSS) or mismatch repair proficient (pMMR) and carry no mutations in the KRAS, NRAS, or BRAF genes (wild-type), and whose cancer worsened after first-line treatment containing an anti-EGFR antibody and chemotherapy.

Approximately 96 eligible participants will be randomly assigned in a 1:1 ratio to one of two treatment groups. Participants in the experimental group (Arm A) will receive serplulimab plus bevacizumab and chemotherapy every 3 weeks, while participants in the control group (Arm B) will receive bevacizumab and chemotherapy every 3 weeks. In both groups, the chemotherapy regimen is chosen based on prior first-line therapy: participants who previously received irinotecan will receive CapeOX (oxaliplatin and capecitabine), and those who previously received oxaliplatin will receive mXELIRI (irinotecan and capecitabine). Treatment will continue until disease progression, unacceptable side effects, withdrawal of consent, or study completion.

研究概览

详细说明

Scientific Rationale:Approximately 95% of patients with advanced or metastatic colorectal cancer (mCRC) harbor microsatellite stable (MSS) or mismatch repair-proficient (pMMR) tumors, a population in which single-agent immune checkpoint inhibitors have demonstrated minimal clinical activity. Preclinical and clinical evidence suggests that cytotoxic chemotherapy (by inducing immunogenic cell death and enhancing antigen presentation) and anti-angiogenic therapy such as bevacizumab (by promoting cytotoxic T-lymphocyte infiltration while reducing regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages) can reprogram the immunosuppressive tumor microenvironment and synergize with PD-1 blockade. Serplulimab (HLX10), a humanized anti-PD-1 IgG4 monoclonal antibody, combined with bevacizumab and XELOX previously demonstrated a substantial progression-free survival (PFS) improvement in first-line mCRC (ASTRUM-015 study). This study investigates whether adding serplulimab to standard second-line bevacizumab plus chemotherapy improves clinical outcomes specifically in patients with left-sided, RAS/BRAF wild-type, MSS/pMMR mCRC following disease progression on first-line anti-EGFR monoclonal antibody therapy.

研究类型

介入性

注册 (估计的)

96

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Liaoning
      • Shenyang、Liaoning、中国、11000
        • Liaoning Provincial Cancer Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Voluntarily agree to participate in the study and sign the written informed consent form.
  • Pathologically confirmed left-sided, microsatellite stable (MSS) or mismatch repair-proficient (pMMR), KRAS/NRAS/BRAF wild-type advanced metastatic colorectal adenocarcinoma.
  • Disease progression following prior first-line standard therapy (anti-EGFR monoclonal antibody combined with chemotherapy).
  • Aged >= 18 years, regardless of sex.
  • Expected survival >= 3 months.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
  • Adequate hematologic function within 14 days prior to enrollment: hemoglobin >= 90 g/L (without blood transfusion within 14 days), absolute neutrophil count >= 1.5 x 10^9/L, and platelet count >= 80 x 10^9/L.
  • Adequate hepatic and renal function within 14 days prior to enrollment: total bilirubin <= 1.5 x upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN (or <= 5 x ULN in patients with liver metastases); and endogenous creatinine clearance >= 60 mL/min (calculated using the Cockcroft-Gault formula).
  • Left ventricular ejection fraction (LVEF) >= 50% as assessed by Doppler echocardiography.
  • Negative serum pregnancy test within 14 days prior to treatment initiation for women of childbearing potential; eligible male and female patients of childbearing potential must agree to use reliable contraceptive methods (hormonal methods, barrier methods, or abstinence) with their partners during the study and for at least 6 months after the last dose of study treatment.

Exclusion Criteria:

  • Currently participating in another interventional drug clinical trial (non-interventional clinical studies are permitted).
  • History of or concurrent other malignancies, except for cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the cervix or breast.
  • Known central nervous system (CNS) metastases (for patients with clinically suspected CNS metastases, CT or MRI must be performed within 28 days prior to treatment initiation to exclude CNS metastases).
  • Clinically symptomatic pleural effusion or ascites requiring clinical intervention.
  • Current use of immunosuppressive agents for any reason, or systemic corticosteroid therapy for immunosuppressive purposes (at a dose > 10 mg/day of prednisone or equivalent).
  • Presence of any active autoimmune disease (including, but not limited to, autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, or nephritis).
  • History of organ transplantation.
  • Concurrent hyperthyroidism.
  • Concurrent vitiligo.
  • History of inflammatory bowel disease (such as ulcerative colitis or Crohn's disease) or chronic diarrheal diseases (such as irritable bowel syndrome).
  • History of sarcoidosis or tuberculosis.
  • Active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection.
  • Newly diagnosed angina pectoris within 3 months prior to screening or myocardial infarction within 6 months prior to screening; cardiac arrhythmia (including QTcF >= 450 ms in males or >= 470 ms in females) requiring long-term antiarrhythmic medication; or New York Heart Association (NYHA) Class >= II cardiac insufficiency.
  • Asthma requiring medical intervention with bronchodilators (patients with childhood asthma that has completely resolved and requires no intervention in adulthood may be included).
  • Infectious pneumonia, non-infectious pneumonia, interstitial pneumonia, or other pulmonary inflammation requiring corticosteroid therapy.
  • History of psychotropic substance abuse with inability to abstain, or psychiatric disorders.
  • Urinalysis showing urine protein >= 2+ and 24-hour urinary protein quantification > 1.0 g.
  • Known hereditary or acquired bleeding and thrombotic tendencies (such as hemophilia, coagulation disorders, thrombocytopenia, hypersplenism, etc.) or currently receiving thrombolytic or anticoagulant therapy.
  • Active bleeding or high risk of bleeding, such as significant bleeding tendency within 3 months prior to enrollment.
  • Other conditions judged by the investigator that may affect study results or lead to premature study discontinuation, such as substance abuse, severe illnesses (including psychiatric disorders such as epileptic seizures), or other medical, psychological, or social conditions that may compromise patient safety or compliance.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm A: Serplulimab Plus Bevacizumab and Chemotherapy

Participants receive serplulimab (300 mg, Day 1) plus bevacizumab (7.5 mg/kg, Day 1) and chemotherapy every 3 weeks (Q3W). The chemotherapy regimen is determined by prior first-line therapy: participants previously treated with an irinotecan-containing regimen receive CapeOX (oxaliplatin 130 mg/m2 on Day 1 plus capecitabine 1000 mg/m2 on Days 1-14, Q3W), while those previously treated with an oxaliplatin-containing regimen receive mXELIRI (irinotecan 200 mg/m2 on Day 1 plus capecitabine 800 mg/m2 on Days 1-14, Q3W). Local antitumor therapy (such as radiotherapy or radiofrequency ablation) for localized metastases is permitted. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Serplulimab (HLX10, Hansizhuang; manufactured by Shanghai Henlius Biotech, Inc.) is administered at a fixed dose of 300 mg on Day 1 of each 21-day (3-week) cycle. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

其他名称:
  • HLX10
  • 韩四庄

Bevacizumab (Hanbeitai; manufactured by Shanghai Henlius Biotech, Inc.) is administered at a dose of 7.5 mg/kg on Day 1 of each 21-day (3-week) cycle. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Administered as part of the CapeOX regimen only to participants who previously received an irinotecan-containing first-line regimen. Oxaliplatin is given at a dose of 130 mg/m2 on Day 1 of each 21-day (3-week) cycle until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Administered as part of the mXELIRI regimen only to participants who previously received an oxaliplatin-containing first-line therapy. Irinotecan is given at a dose of 200 mg/m2 on Day 1 of each 21-day (3-week) cycle until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Administered on Days 1 to 14 of each 21-day (3-week) cycle, with the dose determined by the chemotherapy backbone assigned based on prior first-line therapy:

In the CapeOX regimen (for participants previously treated with an irinotecan-containing regimen): 1000 mg/m2 on Days 1-14, every 3 weeks.

In the mXELIRI regimen (for participants previously treated with an oxaliplatin-containing regimen): 800 mg/m2 on Days 1-14, every 3 weeks.

Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

有源比较器:Arm B: Bevacizumab Plus Chemotherapy

Participants receive bevacizumab (7.5 mg/kg, Day 1) plus chemotherapy every 3 weeks (Q3W). The chemotherapy regimen is determined by prior first-line therapy: participants previously treated with an irinotecan-containing regimen receive CapeOX (oxaliplatin 130 mg/m2 on Day 1 plus capecitabine 1000 mg/m2 on Days 1-14, Q3W), while those previously treated with an oxaliplatin-containing regimen receive mXELIRI (irinotecan 200 mg/m2 on Day 1 plus capecitabine 800 mg/m2 on Days 1-14, Q3W). Local antitumor therapy (such as radiotherapy or radiofrequency ablation) for localized metastases is permitted. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Bevacizumab (Hanbeitai; manufactured by Shanghai Henlius Biotech, Inc.) is administered at a dose of 7.5 mg/kg on Day 1 of each 21-day (3-week) cycle. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Administered as part of the CapeOX regimen only to participants who previously received an irinotecan-containing first-line regimen. Oxaliplatin is given at a dose of 130 mg/m2 on Day 1 of each 21-day (3-week) cycle until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Administered as part of the mXELIRI regimen only to participants who previously received an oxaliplatin-containing first-line therapy. Irinotecan is given at a dose of 200 mg/m2 on Day 1 of each 21-day (3-week) cycle until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Administered on Days 1 to 14 of each 21-day (3-week) cycle, with the dose determined by the chemotherapy backbone assigned based on prior first-line therapy:

In the CapeOX regimen (for participants previously treated with an irinotecan-containing regimen): 1000 mg/m2 on Days 1-14, every 3 weeks.

In the mXELIRI regimen (for participants previously treated with an oxaliplatin-containing regimen): 800 mg/m2 on Days 1-14, every 3 weeks.

Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
9-Month Progression-Free Survival (PFS) Rate
大体时间:At 9 months after treatment initiation

The proportion of participants who are alive and free of radiographic disease progression at 9 months after the initiation of study treatment. Tumor assessments are performed at baseline and every 6 weeks (±7 days) during treatment using contrast-enhanced CT or MRI according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

At 9 months after treatment initiation

次要结果测量

结果测量
措施说明
大体时间
Progression-Free Survival (PFS)
大体时间:From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)

Defined as the time from the initiation of study treatment to the first documented disease progression (evaluated by investigators according to RECIST v1.1) or death from any cause, whichever occurs first, estimated using the Kaplan-Meier method. Tumor assessments (contrast-enhanced CT or MRI) are performed at baseline and every 6 weeks (±7 days) thereafter.

From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)
Objective Response Rate (ORR)
大体时间:From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)

The percentage of participants achieving a complete response (CR) or partial response (PR) as their best overall response, evaluated by investigators according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Tumor assessments (contrast-enhanced CT or MRI) are performed at baseline and every 6 weeks (±7 days) thereafter.

From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)
Disease Control Rate (DCR)
大体时间:From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)

The percentage of participants achieving a complete response (CR), partial response (PR), or stable disease (SD) as their best overall response, evaluated by investigators according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Tumor assessments (contrast-enhanced CT or MRI) are performed at baseline and every 6 weeks (±7 days) thereafter.

From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)
Overall Survival (OS)
大体时间:From enrollment until death from any cause, assessed every 3 months during the first year after treatment discontinuation and every 6 months thereafter up to study completion (approximately 24 months)

Defined as the time from enrollment to death from any cause, estimated using the Kaplan-Meier method. Participants who are still alive at the last follow-up will be censored at the date of last known survival.

From enrollment until death from any cause, assessed every 3 months during the first year after treatment discontinuation and every 6 months thereafter up to study completion (approximately 24 months)
Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:From signing of informed consent through 30 days after the last dose of study treatment (or until initiation of new antitumor therapy, whichever occurs first)

Number and percentage of participants experiencing adverse events (AEs) and serious adverse events (SAEs), as well as clinically significant changes in laboratory tests, vital signs, 12-lead electrocardiograms, and echocardiograms. Toxicity severity is graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0).

From signing of informed consent through 30 days after the last dose of study treatment (or until initiation of new antitumor therapy, whichever occurs first)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2028年6月30日

研究完成 (估计的)

2029年6月30日

研究注册日期

首次提交

2026年11月16日

首先提交符合 QC 标准的

2026年11月16日

首次发布 (实际的)

2026年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅